Resverlogix Announces Voting Results From The 2017 Annual Meeting Of Shareholders
December 12 2017 - 8:08PM
Resverlogix Corp. (“Resverlogix”, or the "Corporation") (TSX:RVX)
announced today that, at its annual meeting of shareholders held on
December 12, 2017, Resverlogix shareholders approved all
resolutions outlined in the Notice of Meeting and Management
Information Circular dated October 30, 2017 (the “Information
Circular”), which is available on SEDAR at www.sedar.com, and on
the Resverlogix website at www.resverlogix.com.
1. Fixing the Number of Directors and
Election of Directors
By resolution passed by ballot vote, each of the
six nominees proposed as a director were elected as directors of
the Corporation to hold office until the next annual meeting of
Shareholders or until their successors are elected or
appointed.
The voting results for each nominee is set out
below:
|
Votes
For |
Votes Withheld |
Percent For |
Percent Withheld |
|
|
|
|
|
Donald
J. McCaffrey |
33,234,615 |
172,543 |
99.48 |
0.52 |
Norma
Biln |
33,299,805 |
107,353 |
99.68 |
0.32 |
Shawn
Lu |
33,187,705 |
219,453 |
99.34 |
0.66 |
Kelly
McNeill |
33,302,505 |
104,653 |
99.69 |
0.31 |
Dr.
Eldon Smith |
33,299,805 |
107,353 |
98.68 |
0.32 |
Kenneth
Zuerblis |
33,319,505 |
87,653 |
99.74 |
0.26 |
|
|
|
|
|
2. Appointment of
Auditors
By resolution passed by show of hands, KPMG LLP,
Chartered Accountants, was appointed as auditor of the Corporation
to hold office until the next annual general meeting of the
Shareholders and to authorize the Board to fix the auditor’s
remuneration.
About Resverlogix
Resverlogix is developing apabetalone (RVX-208),
a first-in-class, small molecule that is a selective BET
(bromodomain and extra-terminal) inhibitor. BET bromodomain
inhibition is an epigenetic mechanism that can regulate
disease-causing genes. Apabetalone is the first and only BET
inhibitor selective for the second bromodomain (BD2) within the BET
protein called BRD4. This selective inhibition of apabetalone on
BD2 produces a specific set of biological effects with potentially
important benefits for patients with high-risk cardiovascular
disease (CVD), diabetes mellitus (DM), chronic kidney disease,
end-stage renal disease treated with hemodialysis,
neurodegenerative disease, Fabry disease, peripheral artery disease
and other orphan diseases, while maintaining a well described
safety profile. Apabetalone is the only selective BET bromodomain
inhibitor in human clinical trials. Apabetalone is currently being
studied in a Phase 3 trial, BETonMACE, in high-risk CVD patients
with type 2 DM and low high-density lipoprotein (HDL), and is
expected to be initiated in a Phase 2a kidney dialysis trial
designed to evaluate biomarker changes and safety parameters in up
to 30 patients with end-stage renal disease treated with
hemodialysis.
Resverlogix common shares trade on the Toronto Stock Exchange
(TSX:RVX).
Follow us on
Twitter: https://mobile.twitter.com/resverlogix_rvx
For further information please contact:
Investor Relations Email: ir@resverlogix.com Phone: 403-254-9252
Or visit our website: www.resverlogix.com
Resverlogix (TSX:RVX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Resverlogix (TSX:RVX)
Historical Stock Chart
From Sep 2023 to Sep 2024